Top

General Thoracic and Cardiovascular Surgery

Published in:

01-11-2016 | Original Article

Prognostic significance of preoperative serum Krebs von den Lungen-6 level in non-small cell lung cancer

Authors: Masaki Tomita, Takanori Ayabe, Eiichi Chosa, Naohiro Nose, Kunihide Nakamura

Published in: General Thoracic and Cardiovascular Surgery | Issue 11/2016

Abstract

Objectives

We retrospectively analyzed the prognostic significance of preoperative serum Krebs von den Lungen-6 (KL-6) level in non-small cell lung cancer (NSCLC) patients.

Methods

We enrolled 175 NSCLC patients who underwent curative surgery between 2009 and 2011. We subdivided the patients into 2 groups: with and without interstitial lung disease (ILD). Prognostic significance of serum KL-6 level was examined.

Results

The 5-year survival of patients with high serum KL-6 level was poor. Multivariate analysis also revealed the prognostic significance of serum KL-6 level. Serum KL-6 level was also a prognostic factor for patients without ILD. Although the number of patients with ILD was small, in patients with ILD, there was a trend towards an association between serum KL-6 level and patients’ prognosis but this did not reach statistical significance.

Conclusions

Serum KL-6 level is a prognostic factor for resected NSCLC patients, especially patients without ILD. There is a possibility that serum KL-6 level is a prognostic marker regardless of the presence of ILD.

Kohno N, Inoue Y, Hamada H, Fujioka S, Fujino S, Yokoyama A, et al. Difference in sero-diagnostic values among kl-6-associated mucins classified as cluster 9. Int J Cancer Suppl. 1994;8:81–3.CrossRefPubMed

Stahel RA, Gilks WR, Lehmann HP, Schenker T. Third international workshop on lung tumor and differentiation antigens: overview of the results of the central data analysis. Int J Cancer Suppl. 1994;8:6–26.CrossRefPubMed

Hirasawa Y, Kohno N, Yokoyama A, Inoue Y, Abe M, Hiwada K. Kl-6, a human muc1 mucin, is chemotactic for human fibroblasts. Am J Respir Cell Mol Biol. 1997;17:501–7.CrossRefPubMed

Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen kl-6. Chest. 1989;96:68–73.CrossRefPubMed

Kohno N, Awaya Y, Oyama T, Yamakido M, Akiyama M, Inoue Y, et al. Kl-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis. 1993;148:637–42.CrossRefPubMed

Inata J, Hattori N, Yokoyama A, Doi M, Ishikawa N, et al. Circulating kl-6/muc1 mucin carrying sialyl lewisa oligosaccharide is an independent prognostic factor in patients with lung adenocarcinoma. Int J Cancer. 2007;120:2643–9.CrossRefPubMed

Shoji F, Yamazaki K, Kouso H, Mori R, Takeo S. Predictive impact for postoperative recurrence of preoperative serum Krebs von den Lungen-6 concentration in pathologic stage ia non-small cell lung cancer. Ann Thorac Surg. 2016;101:1903–8.CrossRefPubMed

Tanaka S, Hattori N, Ishikawa N, Shoda H, Takano A, Nishino R, et al. Krebs von den Lungen-6 (kl-6) is a prognostic biomarker in patients with surgically resected nonsmall cell lung cancer. Int J Cancer. 2012;130:377–87.CrossRefPubMed

Kawasaki H, Nagai K, Yoshida J, Nishimura M, Nishiwaki Y. Postoperative morbidity, mortality, and survival in lung cancer associated with idiopathic pulmonary fibrosis. J Surg Oncol. 2002;81:33–7.CrossRefPubMed

10.

Sato T, Watanabe A, Kondo H, Kanzaki M, Okubo K, Yokoi K, et al. Long-term results and predictors of survival after surgical resection of patients with lung cancer and interstitial lung diseases. J Thorac Cardiovasc Surg. 2015;149:64–9 (70.e1–2).CrossRefPubMed

11.

Miyazaki K, Kurishima K, Kagohashi K, Kawaguchi M, Ishikawa H, Satoh H, et al. Serum kl-6 levels in lung cancer patients with or without interstitial lung disease. J Clin Lab Anal. 2010;24:295–9.CrossRefPubMed

12.

Chiyo M, Sekine Y, Iwata T, Tatsumi K, Yasufuku K, Iyoda A, et al. Impact of interstitial lung disease on surgical morbidity and mortality for lung cancer: analyses of short-term and long-term outcomes. J Thorac Cardiovasc Surg. 2003;126:1141–6.CrossRefPubMed

13.

Ogawa Y, Ishikawa T, Ikeda K, Nakata B, Sawada T, Ogisawa K, et al. Evaluation of serum kl-6, a mucin-like glycoprotein, as a tumor marker for breast cancer. Clin Cancer Res. 2000;6:4069–72.PubMed

14.

Xu H, Inagaki Y, Tang W, Guo Q, Wang F, Seyama Y, et al. Elevation of serum kl-6 mucin levels in patients with cholangiocarcinoma. Hepatogastroenterology. 2008;55:2000–4.PubMed

15.

Kimura T, Tanaka S, Haruma K, Sumii K, Kajiyama G, Shimamoto F, et al. Clinical significance of muc1 and e-cadherin expression, cellular proliferation, and angiogenesis at the deepest invasive portion of colorectal cancer. Int J Oncol. 2000;16:55–64.PubMed

16.

Yamasaki H, Ikeda S, Okajima M, Miura Y, Asahara T, Kohno N, et al. Expression and localization of muc1, muc2, muc5ac and small intestinal mucin antigen in pancreatic tumors. Int J Oncol. 2004;24:107–13.PubMed

17.

Kurosaki M, Izumi N, Onuki Y, Nishimura Y, Ueda K, Tsuchiya K, et al. Serum kl-6 as a novel tumor marker for hepatocellular carcinoma in hepatitis c virus infected patients. Hepatol Res. 2005;33:250–7.CrossRefPubMed

18.

Xu F, Liu F, Zhao H, An G, Feng G. Prognostic significance of mucin antigen muc1 in various human epithelial cancers: a meta-analysis. Med (Balt). 2015;94:e2286.CrossRef

19.

Nagai S, Takenaka K, Sonobe M, Ogawa E, Wada H, Tanaka F. A novel classification of muc1 expression is correlated with tumor differentiation and postoperative prognosis in non-small cell lung cancer. J Thorac Oncol. 2006;1:46–51.PubMed

20.

Kinoshita A, Hirose K, Taniguchi T, Soda H, Rikitake T, Tsurukawa Y, et al. [lung cancer associated with idiopathic interstitial pneumonia]. Nihon Kyobu Shikkan Gakkai Zasshi. 1990;28:852–8 (in Japanese).PubMed

21.

Park J, Kim DS, Shim TS, Lim CM, Koh Y, Lee SD, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2001;17:1216–9.CrossRefPubMed

Title: Prognostic significance of preoperative serum Krebs von den Lungen-6 level in non-small cell lung cancer
Authors: Masaki Tomita
Takanori Ayabe
Eiichi Chosa
Naohiro Nose
Kunihide Nakamura
Publication date: 01-11-2016
Publisher: Springer Japan
Published in: General Thoracic and Cardiovascular Surgery / Issue 11/2016
Print ISSN: 1863-6705
Electronic ISSN: 1863-6713
DOI: https://doi.org/10.1007/s11748-016-0706-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prognostic significance of preoperative serum Krebs von den Lungen-6 level in non-small cell lung cancer

Abstract

Objectives

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2016

Erratum to: Surgical indication for functional tricuspid regurgitation at initial operation: judging from long term outcomes

A simple and effective method to apply TachoSil® Tissue Sealing sheet using Esmarch’s bandage

Optimal temperature management in aortic arch operations

Thoracic and cardiovascular surgery in Japan during 2014

Efficacy of limited proximal arch replacement for type A acute aortic dissection with critical complications